#evaluate(de(' #AdditionalMetaTags# '))#
Venturelab
close

Medical device for ophthalmic treatment

EMAGine SA

Swiss Startup - EMAGine Profile Main Image
Incorporated
27.02.2013
Headquarters
Zug
Support

CXL (corneal collagen-cross-linking) is a relatively new ophthalmic treatment that uses UV-light and riboflavin to create biochemical and biomechanical changes that strengthen a compromised or diseased cornea. Initially developped for the traitement of corneal degeneration (keratoconus), recent reports indicate that CXL is also effective in arresting all forms of corneal infections (more frequent than keratoconus). With these findings, Prof. Hafezi and Dr. Olivier Richoz are developing a medical device (C-EyeTip©) to be used for both keratoconus and corneal infection.

Videos and Presentations

Conventional cross-linking treatment (CXL) requiring an operating theatre

Human cornea: shift from normal to keratoconus

Cross-links in the human cornea